Two phase II late-breaking plenary oral abstracts at ACR offered tantalizing suggestions that could inform a successful phase III effort. Other presentations of note focused on the importance of patient-reported outcomes and the intriguing potential of studying already approved drugs in SLE.
The 2014 American College of Rheumatology annual meeting provided us with new and promising data on the safety and efficacy of current and investigational agents. How soon will we have new treatment options for patients with PsA?
Research presented at the 2014 ACR annual meeting showed that targeting the IL-23/IL-17 axis in ankylosing spondylitis led to high ASAS20 responses, and the use of TNF inhibitors benefits patients with nonradiographic axial spondyloarthritis.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.